Speech Disorders Clinical Trial
Official title:
An Open-label Study to Evaluate the Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).
Verified date | October 2016 |
Source | CITrials |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The primary objective of this study is to evaluate the efficacy and tolerability of ecopipam
in reducing stuttering symptoms.
It is hypothesized that ecopipam effectively reduces stuttering symptoms as measured on the
SSI-IV total score, the CGI, SSS and OASES.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | November 2017 |
Est. primary completion date | August 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: Subjects can be enrolled in the study only if they meet all of the following criteria: 1. Subjects must satisfy DSM-IV criteria for childhood onset fluency disorder (stuttering). 2. The nature of stuttering must be developmental in origin with the onset prior to ten years of age. 3. Subjects must have a score of moderate or higher on the SSI-IV. 4. Women of child-bearing potential are eligible to participate as long as they are practicing a medically accepted form of contraception (i.e. condom with spermicide or diaphragm, oral or depot contraception, or an intrauterine device). 5. Subjects will be male or female from the ages of 18-60. 6. Subject must have a MADRS total score of = 13 (normal mood) 7. Subjects will be of only English speaking. Exclusion Criteria: Subjects will be excluded from the study for any of the following reasons: 1. Adult individuals who lack capacity to consent for themselves. 2. Stuttering related to a known neurologic cause (e.g. head trauma, stroke). 3. Unstable medical or psychiatric illness. 4. Active substance abuse within three months prior to study inclusion. 5. Any illness that would require the concomitant use of a CNS active medication during the course of the study. 6. Subjects with Parkinson's dementia or other degenerative neurologic illness. 7. Suffer from irregular heart rate or seizures 8. Subjects who are pregnant or nursing an infant. 9. Subject with a MADRS = 14 10. Breastfeeding a child during the course of the study or for one month following completion 11. It is the investigator's opinion that the subject poses a significant suicide risk by the following criteria: 1. It is the investigator's opinion that the subject may be at risk of suicide. 2. the subject responds "yes" to question #4 (Active Suicidal Ideation with Specific Plan and Intent) on the Baseline Visit of the Columbia Suicide Severity Rating Scale (C-SSRS), if the most recent episode occurred within the past 12 months. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | CITrials | Riverside | California |
United States | University of California Riverside School of Medicine | Riverside | California |
Lead Sponsor | Collaborator |
---|---|
Gerald Maguire, MD | University of California Riverisde School of Medicine |
United States,
Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE. A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol. 2014 Jan-Feb;37(1):26-30. doi: 10.1097/WNF.0000000000000017. — View Citation
Maguire G, Franklin D, Vatakis NG, Morgenshtern E, Denko T, Yaruss JS, Spotts C, Davis L, Davis A, Fox P, Soni P, Blomgren M, Silverman A, Riley G. Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: the EXamining Pa — View Citation
Maguire GA, Riley GD, Franklin DL, Gottschalk LA. Risperidone for the treatment of stuttering. J Clin Psychopharmacol. 2000 Aug;20(4):479-82. — View Citation
Maguire GA, Riley GD, Franklin DL, Maguire ME, Nguyen CT, Brojeni PH. Olanzapine in the treatment of developmental stuttering: a double-blind, placebo-controlled trial. Ann Clin Psychiatry. 2004 Apr-Jun;16(2):63-7. — View Citation
Maguire GA, Riley GD, Yu BP. A neurological basis of stuttering? Lancet Neurol. 2002 Nov;1(7):407. Review. — View Citation
Maguire GA, Yu BP, Franklin DL, Riley GD. Alleviating stuttering with pharmacological interventions. Expert Opin Pharmacother. 2004 Jul;5(7):1565-71. Review. — View Citation
Riley J, Riley G, Maguire G. Subjective Screening of Stuttering severity, locus of control and avoidance: research edition. J Fluency Disord. 2004;29(1):51-62. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the Stuttering Severity Instrument Version IV (SSI-IV) | This is an objective measure of stuttering in which it captures verbal samples of five minutes speaking during a conversation and 5 minutes of reading a passage. | This scale is completed on Visit 1/screening and Visit 5/week 8. | No |
Secondary | Clinical Global Impression Scale-Severity (CGI-S) | This is an evaluation of the patient by the investigator as to whether or not the subjects has improved, remained the same, or worsened while in the study. | This scale is completed on Visit 1/screening, Visit 2/baseline, Visit 3/week 2, and Visit 5/week 8. | No |
Secondary | Subjective Stuttering Scale (SSS) | This scale is completed on Visit 2/baseline and Visit 5/week 8. | No | |
Secondary | Overall Assessment of the Speaker's Experience of Stuttering (OASES) | This scale is completed on Visit 2/baseline and Visit 5/week 8. | No | |
Secondary | Montgomery Asberg Depression Rating Scale (MADRS) | An observer-rated depression scale | This scale is completed on Visit 2/baseline, Visit 3/week 2, Visit 4/week 4 and Visit 5/week 8. | Yes |
Secondary | Barnes Akathisia Scale (BAS) | measures how restless the subject is during the examination | This scale is completed on Visit 1/screening, Visit 5/week 8. | Yes |
Secondary | Abnormal Involuntary Movement Scale (AIMS) | This scale is completed on Visit 1/screening, Visit 5/week 8. | Yes | |
Secondary | Columbia-Suicide Severity Rating Scale (C-SSRS) | This scale is completed on Visit 1/screening, Visit 2/baseline, Visit 3/week 2, Visit 4/week 4 and Visit 5/week 8. | Yes | |
Secondary | Simpson Angus Scale (SAS) | This scale is completed on Visit 1/screening, Visit 5/week 8. | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05695131 -
Clinical Feasibility & Validation of the Virtual Reality GlenxRose Speech-Language Therapies
|
N/A | |
Recruiting |
NCT04117360 -
Orthognathic Speech Pathology: Phonetic Contrasts of Patients With Dental Discrepancies Pre- and Post-Treatment Analyses
|
||
Completed |
NCT02288598 -
Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering
|
N/A | |
Completed |
NCT02490826 -
Table to Tablet (T2T): A Novel Intervention Framework for Children With Speech Sound Disorders
|
N/A | |
Not yet recruiting |
NCT04528147 -
Yi Jin Jing Tiger Roaring Speech Rehabilitation With Real-Time Feedback Technique for PD
|
N/A | |
Completed |
NCT02554513 -
Apraxia of Speech: Comparison of EPG Treatment (Tx) and Sound Production Treatment (SPT)
|
N/A | |
Recruiting |
NCT05876247 -
Articulatory Adaptation Following Oral Cancer Treatment
|
||
Recruiting |
NCT05489965 -
Gender Disparities in Voice Outcomes After Tracheoesophageal Puncture in Total Laryngectomy Patients (UC Davis)
|
||
Completed |
NCT02752425 -
Visual Feedback of Tongue by Ultrasound Echography for Speech Trouble Rehabilitation
|
N/A | |
Recruiting |
NCT06443073 -
The Mere-measurement Effect of Patient-reported Outcomes
|
N/A | |
Recruiting |
NCT05741853 -
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
|
N/A | |
Completed |
NCT04026581 -
Real World Testing of a Brain-Computer Interface
|
||
Active, not recruiting |
NCT04937452 -
Dopaminergic Therapy for Frontotemporal Dementia Patients
|
Phase 2 | |
Completed |
NCT02416856 -
Brain Connectivity Supporting Language Recovery in Aphasia
|
||
Completed |
NCT01180309 -
Lingual Frenum and Articulation of Phonemes
|
N/A | |
Completed |
NCT03663972 -
Age-related Correlates of Treatment for Late-acquired Sounds
|
N/A | |
Not yet recruiting |
NCT04323085 -
Speech-in-Noise Treatments for Hypophonia in Parkinson's Disease
|
Phase 2 | |
Completed |
NCT00125242 -
Word-Retrieval Treatment for Aphasia: Semantic Feature Analysis
|
N/A | |
Completed |
NCT04966689 -
The Effect of Combined Speech and Music-therapy on the Speech Characteristics of People With Parkinson's Disease (PD)
|
N/A | |
Completed |
NCT04009811 -
A New Membrane Obturator Prothesis Concept for Soft Palate Defects
|
N/A |